. . "Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . . . . . . . . . . . . . . . "Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer"@en . . . . . . . . . . . . . . . . . . . . . "clinical trial"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "2007-11-02T00:00:00Z"^^ . . . . . . . . . . . . . "Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer"@nl . . . . . . . . . . . . . . . . . . . . . . . . . . . "2016-09-30T00:00:00Z"^^ . . . . . . . . "4890"^^ . . . . . . . . "ensayu cl\u00EDnicu"@ast . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "NCT00433511" . . . . . . . "Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer"@en . . . . . . . . . . . . . . "18"^^ . . . . "klinisch onderzoek"@nl . "Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer"@nl . . . . . . . . . . . . . . "A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer"@en . . . . . . . . . . . . . . . . . "Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer"@nl .